Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: The need for a more tailored dosing regimen

European Journal of Haematology

Volumn 77, Issue 6, 2006, Pages 457-462

  Sconce, Elizabeth A ^a   Kamali, Farhad ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Anticoagulation; Atrial fibrillation; Thromboembolism; Vitamin K; Warfarin

Indexed keywords

ANTILIPEMIC AGENT; CYTOCHROME P450 2C9; MENADIOL SODIUM PHOSPHATE; OXIDOREDUCTASE; PHYTOMENADIONE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; VITAMIN K GROUP; WARFARIN;

ABSENCE OF SIDE EFFECTS; ALGORITHM; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; BODY WEIGHT; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; OVER ANTICOAGULATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; GENOTYPE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 33750621457     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.0902-4441.2006.t01-1-EJH2957.x     Document Type: Review

References (46)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from 5 randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
2. HART R, BENAVENTE O, MCBRIDE R, PEARCE L. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
3. VAN WALRAEVEN C, HART RG, SINGER DE, LAUPACIS A, CONNOLLY S, PETERSON P, KOUDSTAAL PJ, CHANG Y, HELLEMONS B. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-2448.
4. HIRSCH J, VALENTIN F. Special Report: Guide to anticoagulant therapy part 2: oral anticoagulants. Circulation 1994;89:1469-1480.
5. FIHN SD, CALLAHAN CM, MARTIN DC, MCDONELL MB, HENIKOFF JG, WHITE RH. The risk and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-979.
6. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation. Lancet 1996;348:633-638.
7. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-416.
8. VEEGER NJGM, PIERSMA-WICHERS M, TIJSSEN JGP, HILLEGE HL, VAN DER MEER J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005;128:513-519.
9. BO S, CICCONE G, SCAGLIONE L. Warfrain for non valvular atrial fibrillation: still underused in the 21st century? Heart 2003;89:553-554.
10. British Committee for Standards Haematology. Guidelines on oral anticoagulation, 3rd edn. Br J Haematol 1998;101:374-378.
11. MAKRIS M, GREAVES M, PHILIPS WS, KITCHEN S, ROSENDAAL FR, PRESTON FR. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477-480.
12. HANLEY JP. Warfarin reversal. J Clin Pathol 2004;57:1132-1139.
13. BAGLIN T. Management of warfarin (coumarin) overdose. Blood Rev 1998;12:91-98.
14. HYLEK EM, CHANG Y, SKATES SJ, HUGHES RA, SINGER DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160:1612-1617.
15. DUONG TM, PLOWMAN BK, MORREALE AP, JANETZKY K. Retrospective and prospective analyses of the treatment of overanticoagulated patients. Pharmacotherapy 1998;18:1264-1270.
16. GUNTHER KE, CONWAY G, LEIBACH L, CROWTHER MA. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR > 10. Thrombosis Research 2004;113:205-209.
17. LUBETSKY A, YONATH H, OLCHOVSKY D, LOEBSTEIN R, HALKIN H, EZRA D. Comparison of oral vs. intravenous phytonadione in patients with excessive anticoagulation. Arch Intern Med 2003;163:2469-2473.
18. WATSON HG, BAGLIN T, LAIDLAW SL, MAKRIS M, PRESTON FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001;115:145-149.
19. PARK BK, SCOTT AK, WILSON AC, HAYNES BP. Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol 1984;18:655-662.
20. CROWTHER MA, JULIAN J, MCCARTY D et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000;356:1551-1553.
21. PENGO V, BANZATO A, GARELLI E, ZASSO A, BIASIOLO A. Reversal of excessive effect of regular anticoagulation; low oral dose of phytonadione (vitamin K) compared to warfarin discontinuation. Blood Coagul Fibrinolysis 1993;4:739-741.
22. MARTINEZ-ABAD M, DELGADO F, PALOP V, MORALES-OLIVAS FJ. Vitamin K and anaphylactic shock. Ann Pharmacother 1991;25:871-872.
23. CROWTHER MA, DOUKETIS JD, SCHNURR T. Oral vitamin K lowers the international normalised ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. Ann Intern Med 2002;137:251-254.
24. LUBETSKY A, SHASHA Y, OLCHOVSKY D, LOEBSTEIN R, HALKIN H, EZRA D. Impact of pre-treatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation. Thromb Haemost 2003;90:71-76.
25. PENDRY K, BHAVANI M, SHWE K. The use of oral vitamin K for reversal of over-warfarinization. Br J Haematol 2001;113:839-842.
26. PATEL RJ, WITT DM, SASEEN JJ, TILMAN DJ, WILKINSON DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000;20:1159-1166.
27. BAKER P, GELGHORN A, TRIPP T, PADDON K, EAGLETON H, KEELING D. Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. Br J Haematol 2006;133:331-336.
28. WITTOWSKY AK, DEVINE EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004;24:1311-1316.
29. WILSON SE, DOUKETIS JD, CROWTHER MA. Treatment of warfarin-associated coagulopathy: a physician survey. Chest 2001;120:1972-1976.
30. LIBBY EN, GARCIA DA. A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med 2002;162:1893-1896.
31. WENTZIEN TH, O'REILLY RA, KEARNS PJ. Prospective evaluation of anticoagulation reversal with oral vitamin K1 while continuing warfarin therapy unchanged. Chest 1998;114:1546-1550.
32. KAMALI F, KHAN T, KING BP, FREARSON R, KESTEVEN P, WOOD P, DALY AK, WYNNE HA. Contribution of age, body size and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004;75:204-212.
33. WYNNE HA, COPE L, KELLY P, WHITTINGHAM T, EDWARDS C, KAMALI F. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 1995;40:203-207.
34. KELLY KC, RAJ G, WEIDERMAN RA. Influence of body weight on response to subcutaneous vitamin K administration in over-anticoagulated patients. Am J Med 2001;110:623-627.
35. HYLEK EM, REGAN S, GO AS, HUGHES RA, SINGER DE, SKATES SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001;135:393-400.
36. LARSEN ML, ILLINGWORTH DR. Drug treatment of dyslipoproteinemia. Med Clin North Am 1994;78:225-245.
37. HIRSCH J. Oral anticoagulant drugs. N Engl J Med 1991;324:1865-1875.
38. WOODHOUSE KW, WYNNE HA, BAILLIE S, JAMES O, RAWLINS MD. Who are the frail elderly? Q J Med 1988;68:506-508.
39. RETTIE AE, WIENKERS LC, GONZALEZ FJ, TRAGER WF, KORZEKWA KR. Impaired (S)-warfarin metabolism catalysed by the R144C allele variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
40. SULLIVAN-KLOSE T, GHANAYEM BI, BELL DA, ZHANG ZY, KAMINSKY LS, SHENFIELD GM. The role of the CYP2C9-Leu 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-349.
41. SCONCE EA, KHAN TI, WYNNE HA, AVERY P, MONKHOUSE L, KING BP, WOOD P, KESTEVEN PJ, DALY AK, KAMALI F. The impact of CYP2C9 and VKORC1 polymorphisms and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-2333.
42. AITHAL GP, DAY CP, KESTEVEN PJL, DALY AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719.
43. CHOONARA IA, MALIA RG, HAYNES BP, HAY CR, CHOLERTON S, BRECKENRIDGE AM, PRESTON FE, PARK BK. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 1988;25:1-7.
44. ROST S, FREGIN A, IVASKEVICIUS V et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537-541.
45. D'ANDREA G, D'AMBROSIO RL, DI PERNA P, CHETTA M, SANTACROCE R, BRANCACCIO V, GRANDONE E, MARGAGLIONE M. A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-649.
46. REITSMA PH, VAN HEIJDEN JF, GROOT AP, ROSENDAAL FR, BULLER HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005;2: e312.